Vetoquinol has reported a 23.7% drop in net income to 48 million euros for the past year, as well as a 2.2% decline in operating income recurring (before amortization of acquired assets) to 98.6 million.

The animal health laboratory reported sales of €539.8 million for 2022, up 3.6% (of which +4.5% for Essentials and +9.1% for the companion animals segment) and down 0.8% at constant exchange rates.

Confident in its ability to deploy its 'Ambition 2026' strategic plan and pursue its sustainable, profitable development, Vetoquinol will propose a dividend of €0.80 per share at the AGM on May 25.

Copyright (c) 2023 CercleFinance.com. All rights reserved.